Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Firm News | November 12, 2025
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Gibson Dunn also advised on a concurrent $285 million private placement by Galecto. Jefferies, Leerink Partners, UBS, and LifeSci are serving as the placement agents to Galecto.
The Gibson Dunn corporate team includes partners Ryan Murr and Branden Berns and associates Evan Shepherd, Maggie Zhang, Chad Kang, and Anika Gidwani. Partner Melanie Neary and associates Nick Linke and Lauren Navarro advised on public company matters; partner Gina Hancock and associate Lucy Hong advised on employee compensation and benefits matters; and partner Pamela Lawrence Endreny and associate Ryan Rott advised on tax matters.